Ocular Services On Demand

What Ocular Services On Demand does

Ocular Services On Demand (OSOD), legally OSOD LLC, is a Madison, Wisconsin-based ophthalmic development services consortium founded in 1993 and acquired by MERIT (Medical Education and Research Institute of Minnesota) in January 2025. The firm aggregates 70+ recognized vision science experts drawn from at least eight North American universities and provides consulting and technical services to pharmaceutical and biotechnology companies developing ocular therapeutics and devices. Its named work has supported the development and FDA approval of major ophthalmic products including Lucentis, Eylea, Susvimo, Xiidra, Durysta, and Retinostat, with cumulative output of more than 2,000 preclinical studies and over 1,000 industry-led studies over the past decade.

OSOD's service portfolio spans the full preclinical arc: efficacy modeling and non-GLP safety studies in preclinical discovery; formulation development and CMC scale-up for toxicology; GLP-compliant toxicology program design, regulatory guidance, and data interpretation in non-clinical development; and technical execution across veterinary ophthalmology support, electrodiagnostics (VEP, PERG, electroretinography), ocular imaging (OCT, fluorescein angiography, ultrasonography), ocular pathology, and species-relevant pharmacology models including glaucoma, choroidal neovascularization, and gene therapy programs. A dedicated quality assurance function underpins the GLP and regulatory work, and the firm coordinates execution through a mix of client on-site engagements, partner CRO facilities, and affiliated university laboratories.

Commercially, OSOD operates as a sales-led B2B consulting consortium with a professional-services revenue model, quote-based pricing, and direct enterprise engagement with pharma and biotech development teams. Customer concentration centers on large-cap pharmaceutical and biotechnology firms (including Regeneron, Genentech/Roche, Shire/Takeda, Allergan/AbbVie, AGTC, and Novartis), supplemented by 40+ industry collaborations. Following the MERIT acquisition, OSOD's preclinical and consulting capabilities are positioned to integrate with MERIT's procedural and surgical infrastructure, broadening the addressable service surface across the ophthalmic development lifecycle.

Name

Ocular Services On Demand

Legal name

OSOD LLC

Website

https://ocularservices.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

Ocular Services On Demand is a Madison, Wisconsin-based consortium of 70+ vision science experts providing preclinical consulting, GLP toxicology, electrodiagnostics, imaging, and pharmacology services to pharmaceutical and biotechnology companies developing ophthalmic therapies and devices, now operating as a MERIT Company.

Ownership category

akta.pro rank

Product category

Ophthalmic Contract Research and Consulting Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), In Vivo Pharmacology (Efficacy/PD Models) (HLAGAFAA), Safety Pharmacology (Cardio/CNS/Respiratory) (HLAGAFAB), DMPK / ADME & Bioanalysis (HLAGAFAC)

Keywords

• Ophthalmic development services
• Preclinical ocular research
• Vision science consulting
• GLP toxicology programs
• Ocular therapeutics consulting

Headquarters

HQ city

Venice

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Professional Services - Consulting: Consulting services for ophthalmic program design, management, and technical execution across all stages of therapy and device development
2. Technical Services: Technical execution of preclinical studies including veterinary ophthalmology, electrodiagnostics, ocular imaging, ocular pathology, and pharmacology models
3. Regulatory and Compliance Services: Quality assurance, regulatory guidance, and GLP compliance services for FDA submissions

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

OSOD is a consortium of 70+ recognized vision science experts delivering consulting and technical services for ophthalmic therapy and device development. Service lines cover Preclinical Discovery (efficacy models, non-GLP safety/tolerability, PK and ocular distribution), Formulation/CMC (discovery and clinical formulation development, drug product scale-up), Non-Clinical Development (regulatory guidance, GLP toxicology program design, data analysis), and Technical Services (veterinary ophthalmology support, electrodiagnostics, ocular imaging, ocular pathology, and pharmacology models). Engagements run from preclinical discovery through regulatory submission for pharmaceutical and biotechnology clients.

Product overview

Ocular Services On Demand (OSOD) is a consortium of recognized vision science experts providing world-class ophthalmic development services to accelerate identification and development of ophthalmic therapies and devices. The company operates as a single unified service offering combining consulting services (preclinical discovery, formulation/CMC, non-clinical development, investigative diligence) with technical services (veterinary ophthalmology support, electrodiagnostics, ocular imaging, ocular pathology, pharmacology models), supported by a dedicated quality assurance team. The company has participated in over 1,000 industry studies, conducted 2,000+ preclinical studies, contributed to 8+ approved ocular therapies, and maintains collaborations with 40+ industry partners and vision science experts across multiple universities.

Differentiator

Problem solved

Functional benefit

Products and services

• Consulting Services Comprehensive consulting services spanning ophthalmic program design, management, and technical execution across preclinical discovery, formulation/CMC, non-clinical development, and investigative diligence. Targeted at pharmaceutical and biotechnology companies developing ocular therapies and devices.
• Preclinical Discovery Efficacy models and non-GLP ocular safety and tolerability studies, including PK and ocular distribution studies, for early-stage ophthalmic therapeutic development.
• Formulation/CMC Discovery formulation development, clinical formulation development, and scale-up of drug product for toxicology studies.
• Non-Clinical Development Clinical and regulatory guidance, GLP toxicology program design and execution, and data analysis and interpretation services for ocular drug development.
• Technical Services Technical services covering veterinary ophthalmology support, electrodiagnostics, ocular imaging, ocular pathology, and pharmacology models for preclinical and translational ocular research.
• Veterinary Ophthalmology Support Specialized ophthalmology support services for veterinary research applications and animal model studies.
• Electrodiagnostics Electrophysiology testing services for ocular function assessment, including VEP, PERG, and electroretinography.
• Ocular Imaging Advanced ocular imaging services for preclinical and diagnostic applications, including OCT, fluorescein angiography, and high-resolution ultrasonography.
• Ocular Pathology Pathology services specialized for ocular tissue analysis and specimen evaluation.
• Pharmacology Models Pharmacology model development and testing services for ocular therapeutics, including animal models of glaucoma, choroidal neovascularization, and other ophthalmic conditions.

Quantifiable outcome

• 8+ Approved Ocular Therapies directly supported through preclinical studies
• +2 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Ten partnerships are on record, tiered core and major.

• MERIT (Medical Education and Research Institute of Minnesota)coreStrategic or Co-development Partner · 22 January 2025MERIT acquired OSOD, integrating OSOD's ophthalmic development services consortium into MERIT's organization. This acquisition combines OSOD's 30+ years of vision science expertise with MERIT's infrastructure to expand service capabilities.
• University of Wisconsin-MadisoncoreStrategic or Co-development PartnerAcademic partnership providing access to university-based vision science laboratories and research resources. OSOD members are located at this university contributing to the consortium's expertise.
• University of California-DaviscoreStrategic or Co-development PartnerAcademic partnership with university-based vision science laboratories and research resources for preclinical ocular studies.
• Texas Tech UniversitycoreStrategic or Co-development PartnerAcademic partnership providing access to vision science expertise and laboratory resources.
• University of HoustoncoreStrategic or Co-development PartnerAcademic partnership with vision science research capabilities.
• Cornell UniversitycoreStrategic or Co-development PartnerAcademic partnership providing access to university-based vision science research expertise.
• Ohio State UniversitycoreStrategic or Co-development PartnerAcademic partnership with vision science research capabilities and laboratory resources.
• Medical University of South CarolinacoreStrategic or Co-development PartnerAcademic partnership including Ola B. Williams Glaucoma Therapeutic Development Center; home to Executive Director Craig Crosson.
• McMaster UniversitycoreStrategic or Co-development PartnerAcademic partnership providing access to Canadian vision science research expertise.
• Preclinical Contract Research Organizations (CROs)majorChannel Partner/ Reseller/ DistributorOSOD collaborates with CROs in preclinical toxicology, ocular DM/PK, and efficacy studies. Services range from protocol review to full integration of OSOD technical teams with CRO facilities. OSOD assists clients in selecting appropriate CROs based on study type, complexity, cost, and timing.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Bionova Scientific: Preclinical CRO providing GLP toxicology, bioanalysis, and cell-line authentication/biologics services. Comparable-sized specialist serving biopharma sponsors with IND-enabling preclinical support, including ophthalmic programs.
• Absorption Systems: U.S.-based preclinical CRO focused on ADME/DMPK and safety pharmacology with specialty capabilities including ocular bioanalysis and small-molecule formulation. Comparable mid-size niche CRO competing for outsourced preclinical development programs.
• EyeCRO: U.S. preclinical ophthalmology CRO providing ocular disease models, pharmacokinetics, and toxicology services for drug developers. Direct peer offering the same species-relevant ocular efficacy and safety capabilities as OSOD.
• Experimentica: Finland-headquartered preclinical CRO specializing exclusively in ophthalmic and diabetes pharmacology models. Direct competitor to OSOD in ocular preclinical efficacy, PK, and safety studies for pharma and biotech sponsors.

Broad incumbents

• Eurofins Discovery: Large global discovery and preclinical CRO with safety assessment, formulation, and bioanalysis capabilities including ophthalmology-adjacent services. Competes for outsourced preclinical work from large pharma clients.
• WuXi AppTec: Global preclinical and clinical CRO with extensive toxicology, DMPK, and safety pharmacology capacity. Targets the same enterprise sponsor preclinical RFPs as OSOD, with broader geographic reach.
• Charles River Laboratories: Large global preclinical CRO with full discovery-to-IND toxicology, safety pharmacology, and DMPK capabilities. Competes with OSOD for ocular preclinical work as part of its broad safety assessment portfolio, especially on GLP toxicology programs for pharma sponsors.
• Inotiv: Preclinical CRO with research models and services including ocular toxicology, safety pharmacology, and DMPK. Provides bundled preclinical capabilities that overlap with OSOD's service offering for similar pharma clients.
• Labcorp Drug Development (formerly Covance): Global CRO offering preclinical and clinical development services including safety assessment, ophthalmology models, and bioanalysis. Competes for the same enterprise pharma preclinical outsourcing budgets as OSOD.

Others

• MERIT (parent): Medical Education and Research Institute organization that acquired OSOD in January 2025. Acts as OSOD's parent and platform of integration; not a competitor but shapes scaling and cross-sell dynamics.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/osod-ocular-services-on-demand

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ocular Services On Demand